TipRanks on MSN
Bristol-Myers Squibb’s New Phase 3 Study: A Potential Game-Changer for Bipolar-I Disorder Treatment
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Dr. Kennedy answers the question: 'Carbamazepine For Bipolar Disorder?' — -- Question: How is carbamazepine (Tegretol) used in the treatment of bipolar disorder? What are the side effects and ...
Bipolar disorder treatment often includes some combination of medications like mood stabilizers and antidepressants alongside therapy.
News-Medical.Net on MSN
Mount Sinai receives $4.5 million grant to investigate neural mechanisms underlying bipolar disorder
The Icahn School of Medicine at Mount Sinai is pleased to announce it has received a three-year, $4.5 million grant from BD2: ...
Dr. Calabrese answers the question: 'When Can I Stop Taking Bipolar Meds?' — -- Question: How long do I have to take medication for bipolar disorder, and can I stop if I no longer have symptoms?
GlobalData on MSN
FDA approves Teva and Medincell’s bipolar I disorder treatment
Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone), a once-a-month extended-release injectable suspension to treat adult ...
News Medical on MSN
BD² expands global effort to examine the key mechanisms of bipolar disorder
Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research ...
BD² recently announced a fourth round of funding opportunities, inviting teams to apply for up to $4.5 million per grant to undertake groundbreaking research into the genetic, molecular, cellular, ...
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Bipolar disorder is a ...
Bipolar disorder exists on a spectrum rather than as a single, uniform condition. This fundamental characteristic explains why two people with the same diagnosis can experience dramatically different ...
Rapid cycling is when someone with bipolar disorder experiences four or more episodes of mania and depression a year.
TipRanks on MSN
Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer for Bipolar-I Disorder Treatment
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results